AXNX
AXNX Real Time Price USDRecent trades of AXNX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by AXNX's directors and management
Government lobbying spending instances
-
$30,000 Jul 27, 2021 Issue: HEALTH ISSUES
-
$50,000 Apr 19, 2021 Issue: Health Issues
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Devices and methods for fine-tuning alignment of charging device with implanted medical device Sep. 10, 2024
-
Patent Title: Methods and systems for frequency adjustment to optimize charging of implantable neurostimulator Sep. 10, 2024
-
Patent Title: Charger holder Aug. 27, 2024
-
Patent Title: Charger holder Aug. 27, 2024
-
Patent Title: System and method for placement of neurostimulation leads Aug. 20, 2024
-
Patent Title: Neurostimulation leads for trial nerve stimulation and methods of use Jul. 23, 2024
-
Patent Title: Charger holder Jun. 11, 2024
-
Patent Title: Charger holder Jun. 11, 2024
-
Patent Title: Header for an implantable medical device Mar. 26, 2024
-
Patent Title: Trainer for a neurostimulator programmer and associated methods of use with a neurostimulation system Dec. 19, 2023
-
Patent Title: Implantable nerve stimulator having internal electronics without asic and methods of use Sep. 26, 2023
-
Patent Title: Methods for determining neurostimulation electrode configurations based on neural localization Aug. 22, 2023
-
Patent Title: Charging device with off-center coil May. 09, 2023
-
Patent Title: Methods and systems for frequency adjustment to optimize charging of implantable neurostimulator Mar. 14, 2023
-
Patent Title: Neurostimulation leads for trial nerve stimulation and methods of use Nov. 29, 2022
-
Patent Title: Electromyographic lead positioning and stimulation titration in a nerve stimulation system for treatment of overactive bladder Nov. 15, 2022
-
Patent Title: Attachment devices and associated methods of use with a nerve stimulation charging device Nov. 01, 2022
-
Patent Title: Antenna and methods of use for an implantable nerve stimulator Oct. 25, 2022
-
Patent Title: Clinician programmer methods and systems for maintaining target operating temperatures Sep. 13, 2022
-
Patent Title: External pulse generator device and associated methods for trial nerve stimulation Jul. 19, 2022
-
Patent Title: Implantable pulse generator external charger May. 24, 2022
-
Patent Title: External pulse generator device and affixation device for trial nerve stimulation and methods of use Mar. 01, 2022
-
Patent Title: Implantable lead affixation structure for nerve stimulation to alleviate bladder dysfunction and other indication Jan. 04, 2022
-
Patent Title: Patient remote and associated methods of use with a nerve stimulation system Sep. 21, 2021
-
Patent Title: Clinician programmer for use with an implantable neurostimulation lead Sep. 14, 2021
-
Patent Title: Neurostimulation leads for trial nerve stimulation and methods of use Sep. 07, 2021
-
Patent Title: Methods and systems for frequency adjustment to optimize charging of implantable neurostimulator Aug. 10, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of AXNX in WallStreetBets Daily Discussion
Recent insights relating to AXNX
Recent picks made for AXNX stock on CNBC
ETFs with the largest estimated holdings in AXNX
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AXNX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.